[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ii-rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ii-rectal-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100646776","quicksilver-ii-pilot-study-100646776",false,"NCT07688135","Quicksilver II Pilot Study","Quicksilver II Non-inferiority Randomized Controlled Trial: Direct-to-surgery or Neoadjuvant Chemotherapy and Surgery in Margin-clear Stage II or III Rectal Cancer","Inclusion Criteria:\n\n* 18+ years of age\n* able to provide written consent\n* MRI confirmed margin-clear Stage II or III rectal cancer\n\nExclusion Criteria:\n\n* patients with tumour criteria that encourage neoadjuvant treatments regardless of margin-status (e.g. need for a permanent colostomy, T4 category, and one or more pelvic sidewall lymph nodes with a short axis diameter \\>7 mm).\n* Unable to provide consent (e.g., language barrier, cognitive issues).","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot study is being done to answer the following question: Will patients with margin-clear Stage 2 or 3 rectal cancer who don't require a colostomy agree to be randomized to 'surgery only' or 'chemotherapy and then surgery'? Study participants will be randomized to receive either 12 weeks of chemotherapy before rectal cancer surgery or they will proceed directly to surgery. The researchers hypothesize that patients with margin-clear clinical Stage II or III rectal cancer can avoid neo-adjuvant (i.e., pre-operative) radiation and chemotherapy treatments and go directly to surgery. A positive pilot study will support funding requests for a related large efficacy trial; this larger trial, if positive, should lead to an important de-escalation innovation - avoiding use of neo-adjuvant chemoradiation and associated toxicity risks for patients with margin-clear Stage II or III rectal cancer.",[26,27],"Stage II Rectal Cancer","Stage III Rectal Cancer",[29,30,31,32],"rectal cancer","prospective randomized controlled trial","change patient care","direct-to-surgery","NOT_YET_RECRUITING","2026-06-30",{"date":36,"type":37},"2026-07-07","ACTUAL",{"date":39,"type":20},"2026-09",{"date":41,"type":20},"2028-12",{"name":43,"class":44},"Mount Sinai Hospital, Canada","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100289723","phase-2-randomizing-two-radiotherapy-boost-options-to-avoid-rectal-cancer-surgery-100289723","NCT03051464","Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer","MORPHEUS","Inclusion Criteria:\n\n* Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic\u002Ftrans-rectal ultrasound\n* Rectal cancer staged as N0-1 by MRI or EUS\u002FTRUS\n* No metastatic lesion\n* Rectal tumor occupying less than half of the circumference\n* Tumor less than 5 cm on its largest dimension\n* Tumor located at less than 10 cm from the anal verge\n* Tumor penetration less than 5 mm in the mesorectal fat\n* Tumor accessible for brachytherapy\n* Lumen accessible for colonoscopy\n* Patient should be a suitable candidate for brachytherapy and chemotherapy\n* Older than 18 years of age\n* Adequate birth control measures in women of childbearing potential\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with previous pelvic radiation\n* Evidence of distant metastasis\n* Extension of malignant disease to the anal canal\n* Tumors staged as T4\n* Tumors larger than 5 cm in length","80 Years",{"count":55,"type":20},131,[57,58],"PHASE2","PHASE3","A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).",[26,61,62,63,64],"Organ Preservation","Non-operative Treatment","Rectal Cancer (Stage III)","Rectal Cancer Patients",[29,66,67,68,69,70,71,72],"non-operative management","rectal preservation","organ preservation","brachytherapy boost for rectal cancer","low rectal cancer curative treatment","mid rectal cancer curative treatment","rectal brachytherapy","RECRUITING","2026-06-25",{"date":34,"type":37},{"date":77,"type":37},"2017-04-25",{"date":79,"type":20},"2030-01",{"name":81,"class":44},"Sir Mortimer B. Davis - Jewish General Hospital",4]